Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Xalkori (crizotinib)
i
Other names:
PF-002341066, PF002341066, PF02341066, PF1066, PF2341066, PF 002341066, PF 02341066, PF 1066, PF 2341066, PF-02341066, PF-2341066, PF-1066
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(312)
News
Trials
Company:
Pfizer
Drug class:
ALK inhibitor
Related drugs:
‹
entrectinib (178)
alectinib (104)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
unecritinib (6)
APG-2449 (4)
TPX-0131 (4)
envonalkib (3)
TGRX-326 (3)
AZD3463 (2)
OBX02-011 (2)
SY-707 (1)
SY-3505 (1)
NVL-655 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
TY-2136b (0)
dirozalkib (0)
ZG0418 (0)
TSR-011 (0)
entrectinib (178)
alectinib (104)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
unecritinib (6)
APG-2449 (4)
TPX-0131 (4)
envonalkib (3)
TGRX-326 (3)
AZD3463 (2)
OBX02-011 (2)
SY-707 (1)
SY-3505 (1)
NVL-655 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
TY-2136b (0)
dirozalkib (0)
ZG0418 (0)
TSR-011 (0)
›
Associations
(312)
News
Trials
VERI cancer hierarchy
Reset Filters
ALK positive
Non-Hodgkin’s Lymphoma
ALK positive
Non-Hodgkin’s Lymphoma
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ROS1 fusion
Non Small Cell Lung Cancer
ROS1 fusion
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ROS1 rearrangement
Non Small Cell Lung Cancer
ROS1 rearrangement
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK positive
Peripheral T-cell Lymphoma
ALK positive
Peripheral T-cell Lymphoma
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK translocation
Soft Tissue Sarcoma
ALK translocation
Soft Tissue Sarcoma
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
MET amplification
Non Small Cell Lung Cancer
MET amplification
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ROS1 fusion
Melanoma
ROS1 fusion
Melanoma
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
ALK fusion
Melanoma
ALK fusion
Melanoma
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.